Immune Design Corporation
1102 Columbia Street
Suite 104
Seattle
Washington
98104
United States
Website: http://www.immunedesign.com/
116 articles about Immune Design Corporation
-
Merck Completes Tender Offer to Acquire Immune Design
4/2/2019
Merck, known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Immune Design at a purchase price of $5.85 per share.
-
Merck Begins Tender Offer to Acquire Immune Design
3/5/2019
Merck, known as MSD outside the United States and Canada, is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design.
-
Merck to Acquire Immune Design
2/21/2019
Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer
-
Shares of Immune Design are skyrocketing in premarket trading today after Merck announced it will acquire the Seattle-based oncology company for $300 million in cash. Immune Design stock has shot up more than 310 percent to $5.83 in early trading.
-
Immune Design Abandons Cancer Vaccine Program, Drops 20% of Workforce at Two U.S. Locations
10/18/2018
The company, with sites in Seattle and South San Francisco, focuses on next-generation oncology therapeutics. It recently completed a portfolio review and decided to focus its energies and existing capital on G100 and abandoned its CMB305 program. -
Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
8/1/2018
G100 advancing to late-stage development following FDA feedback
-
Immune Design is a clinical-stage immunotherapy company.
-
Immune Design's Combination of G100 With KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
12/11/2017
These data were presented at the 59th American Society of Hematology (ASH) Annual meeting in Atlanta, Georgia on Sunday, December 10, 2017.
-
Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update
10/27/2017
Management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 1, 2017.
-
Immune Design Prices $80M Public Offering of Common Stock
10/25/2017
All of the shares of common stock are being offered by Immune Design.
-
Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin's Lymphoma
10/20/2017
G100 is a product candidate from Immune Design's GLAAS discovery platform.
-
Immune Design Announces Positive FDA Feedback on Phase III Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
10/17/2017
The company plans to initiate a pivotal Phase 3 trial to support a Biologics License Application for CMB305.
-
Immune Design Corporation Release: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit And Immune Response
9/8/2017
-
Immune Design Corporation Announces New CMB305 + Checkpoint Inhibitor Topline Data From An Upcoming Presentation At The ESMO 2017 Congress
8/31/2017
-
Immune Design Corporation Announces New CMB305 + Checkpoint Inhibitor Topline Data From An Upcoming Presentation At The ESMO 2017 Congress
8/31/2017
-
Immune Design Corporation Reports Second Quarter 2017 Financial Results And Provides Corporate Update
8/3/2017
-
Immune Design Corporation To Report Second Quarter 2017 Financial Results & Provide Corporate Update
7/26/2017
-
Immune Design Corporation Updates Positive Data From Lead Cancer Immunotherapy Programs At ASCO Annual Meeting
6/5/2017
-
New Clinical And Biomarker Data Validate Immune Design Corporation’s Lead Programs And Discovery Platforms
5/18/2017
-
Immune Design Corporation Reports First Quarter 2017 Financial Results and Provides Corporate Update
5/18/2017